Waldencast plc - Class A Ordinary Share (WALD)

DermFx selected as a leading regional med spa partner due to its commitment to exceptional patient care, aesthetic innovation, and excellence across Southern California practices

Moxie selected as a leading aesthetic practice software and support partner for its commitment to innovation, compliance, and empowering aesthetic entrepreneurs

The dermatologist-tested duo pairs gentle chemical resurfacing with daily hydration and SPF protection for visibly smoother lips

VIO Med Spa selected as a key med spa franchise partner for its commitment to clinical excellence, innovation, and nationwide scalable aesthetic care

Next Health selected as a leading wellness and longevity partner given its innovative approach to personalized aesthetics and health optimization

Alpha selected as the first Medspa platform partner given their commitment to innovation, education, and breaking through barriers

Alpha selected as the first Medspa platform partner given their commitment to innovation, education, and breaking through barriers

Platinum selected as the first dermatology platform partner due to its commitment to clinical evidence and dissemination across its network of practices

Platinum selected as the first dermatology platform partner due to its commitment to clinical evidence and dissemination across its network of practices

Program Designed to Drive Real World, Practice Focused Evidence with Injectables & Skincare

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Waldencast plc (“Waldencast” or the “Company”) (NASDAQ: WALD).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Waldencast plc (“Waldencast” or the “Company”) (NASDAQ: WALD).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

Transformation efforts drive performance improvements at Obagi Medical with accelerating revenue

Obagi® saypha® ChIQ™ data selected as a top 10 cosmetic oral abstract presentation

NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today announced that it had sold its rights to the “Obagi” trademark in Japan to Rohto Pharmaceutical Co., Ltd. (“Rohto”) for USD $82.5 million.

First Half Fiscal 2025 Results and Q3 2025 Financial Results Expected to be Reported on November 24, 2025

A Next-Generation, Redensifying Scalp Serum Clinically Proven to Promote Fuller, Denser-Looking Hair*

U.S. Launch Planned in 2026 and Positions Obagi Medical as a Leading Dermatological Megabrand at the Convergence of Integrated Skincare and Aesthetics While Doubling its Addressable Market

Obagi Medical delivers H1 2025 double-digit growth in its Core Strategic Channels. Novaestiq Acquisition Doubles the Brand’s Addressable Market in the U.S.

Acquisition strengthens Obagi Medical's product portfolio with proven, scientifically backed, injectable portfolio

Acquisition strengthens Obagi Medical’s product portfolio with proven, scientifically backed, injectable portfolio

Q1 Net Revenue of $65.4 million, (4.1)% decline from Q1 202476.4% Adjusted Gross Margin, an improvement of 10 basis points$4.4 million of Adjusted EBITDA

A Scientific Breakthrough in Skin Renewal: A Clinically Proven Dual-Action, Slow-Release, Overnight Skin Renewal Cream for a Resurfaced, Smoother, and More Even-Looking Complexion

Q4 Net Revenue of $72.1 million, 29.4% Comparable Net Revenue Growth and $11.2 million of Adjusted EBITDA, doubling from Q4 2023